Argenx SE launched a public offering of $150 million of its American depositary shares.
The Netherlands-based biotechnology company granted underwriters an option to buy up to an additional 15% of the ADSs offered.
Each ADS represents the right to receive one ordinary share.
Cowen and Piper Jaffray & Co. are acting as joint book-running managers for the offering, with JMP Securities and Wedbush PacGrow as co-managers. Kempen & Co. is acting as the company's adviser in the offering.
